Privileged structures in drug discovery : (Record no. 643397)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07780cam a2200721Ii 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250919132323.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||unuuu |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 190918s2018 nju ob 001 0 eng d |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER | |
| LC control number | 2017-058921 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118686263 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1118686268 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781118145661 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118686355 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1118686357 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781118686331 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1118686330 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 1118145666 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | GBVCP |
| System control number | 1018224912 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | GBVCP |
| System control number | 1019254106 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | AU@ |
| System control number | 000061348737 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | CHVBK |
| System control number | 516428969 |
| 029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC) | |
| OCLC library identifier | CHNEW |
| System control number | 001003194 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1028552135 |
| Canceled/invalid control number | (OCoLC)1019837899 |
| -- | (OCoLC)1050759573 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)on1028552135 |
| 039 #9 - LEVEL OF BIBLIOGRAPHIC CONTROL AND CODING DETAIL [OBSOLETE] | |
| Level of rules in bibliographic description | 201911011143 |
| Level of effort used to assign nonsubject heading access points | ros |
| y | 09-18-2019 |
| z | hafiz |
| w | UKM UBCM Wiley MARC (363 titles).mrc |
| x | 17 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NST |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | NST |
| Modifying agency | DLC |
| -- | DG1 |
| -- | NST |
| -- | EBLCP |
| -- | RECBK |
| -- | OCLCF |
| -- | UAB |
| -- | MERER |
| -- | UPM |
| -- | OCLCQ |
| -- | CASUM |
| -- | OCLCO |
| -- | WYU |
| -- | OCLCQ |
| -- | OCLCA |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | MAIN |
| 050 10 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS403 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED |
| Subject category code subdivision | 071000 |
| Source | bisacsh |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1/9 |
| Edition information | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Yet, Larry, |
| Relator term | author. |
| 245 10 - TITLE STATEMENT | |
| Title | Privileged structures in drug discovery : |
| Remainder of title | medicinal chemistry and synthesis / |
| Statement of responsibility, etc. | Larry Yet. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Hoboken, NJ : |
| Name of producer, publisher, distributor, manufacturer | Wiley, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2018. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Intro; Title Page; Copyright Page; Contents; Chapter 1 Introduction; 1.1 The Original Definition of Privileged Structures; 1.2 The Role of Privileged Structures in the Drug Discovery Process; 1.3 The Loose Definitions of â#x80;#x9C;Privileged Structuresâ#x80;#x9D;; 1.4 Synthesis and Biological Activities of Carbocyclic and Heterocyclic Privileged Structures; 1.4.1 Synthesis and Biological Activities of Three- and Four-Membered Ring Privileged Structures; 1.4.2 Synthesis and Biological Activities of Five-Membered Ring Privileged Structures |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 1.4.3 Synthesis and Biological Activities of Six-Membered Ring Privileged Structures1.4.4 Synthesis and Biological Activities of Bicyclic 5/5 and 6/5 Ring Privileged Structures; 1.4.5 Synthesis and Biological Activities of Bicyclic 6/6 and 6/7 Ring Privileged Structures; 1.4.6 Synthesis and Biological Activities of Tricyclic and Tetracyclic Ring Privileged Structures; 1.5 Combinatorial Libraries of â#x80;#x9C;Privileged Structuresâ#x80;#x9D;; 1.6 Scope of this Monograph; References; Chapter 2 Benzodiazepines; 2.1 Introduction; 2.2 Marketed BDZ Drugs; 2.2.1 1,4-Benzodiazepine Marketed Drugs |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.2.2 1,5-Benzodiazepine Marketed Drugs2.2.3 Linearly Fused BDZ Marketed Drugs; 2.2.4 Angularly Fused-1,4-Benzodiazepine Marketed Drugs; 2.3 Medicinal Chemistry Case Studies; 2.3.1 Cardiovascular Applications; 2.3.2 Central Nervous System Applications; 2.3.3 Gastrointestinal Applications; 2.3.4 Infectious Diseases Applications; 2.3.5 Inflammation Applications; 2.3.6 Metabolic Diseases Applications; 2.3.7 Oncology Applications; 2.4 Synthesis of BDZs; 2.4.1 Condensation of o-Phenylenediamines to 1,5-Benzodiazepines; 2.4.1.1 Condensation of o-Phenylenediamines with Ketones |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.4.1.2 Condensation of o-Phenylenediamines with α,β-Unsaturated Ketones2.4.1.3 Condensation of o-Phenylenediamines with Alkynes; 2.4.2 Reductive Condensation of α-Substituted Nitrobenzenes with Ketones and α,β-Unsaturated Ketones; 2.4.3 Intramolecular Cyclizations to 1,4-Benzodiazepines; 2.4.3.1 Intramolecular Cyclizationsâ#x80;#x94;Path A; 2.4.3.2 Intramolecular Cyclizationsâ#x80;#x94;Path B; 2.4.3.3 Intramolecular Cyclizationsâ#x80;#x94;Path C; 2.4.3.4 Intramolecular Cyclizationsâ#x80;#x94;Path D; 2.4.3.5 Intramolecular Cyclizationsâ#x80;#x94;Path E; 2.4.3.6 Intramolecular Cyclizationsâ#x80;#x94;Path F |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 2.4.3.7 Intramolecular Cyclizationsâ#x80;#x94;Path G2.4.3.8 Intramolecular Cyclizationsâ#x80;#x94;Path H; 2.4.4 Ugi Multicomponent Synthesis; 2.4.5 Elaboration of 1,4-Benzodiazepines; 2.4.6 Pyrrolo[2,1-c]benzodiazepines; 2.4.7 Fused BDZ Ring Systems; 2.4.8 Solid-Phase Synthesis of BDZs; References; Chapter 3 1,4-Dihydropyridines; 3.1 Introduction; 3.2 Marketed 1,4-Dihyropyridine Drugs; 3.3 Medicinal Chemistry Case Studies; 3.3.1 Cardiovascular Applications; 3.3.2 Central Nervous System Applications; 3.3.3 Infectious Diseases Applications; 3.3.4 Inflammation Applications |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.3.5 Menâ#x80;#x99;s and Womenâ#x80;#x99;s Health Issues Applications |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | A comprehensive guide to privileged structures and their application in the discovery of new drugs The use of privileged structures is a viable strategy in the discovery of new medicines at the lead optimization stages of the drug discovery process. Privileged Structures in Drug Discovery offers a comprehensive text that reviews privileged structures from the point of view of medicinal chemistry and contains the synthetic routes to these structures. In this text, the author-a noted expert in the field-includes an historical perspective on the topic, presents a practical compendium to privileged structures, and offers an informed perspective on the future direction for the field. The book describes the up-to-date and state-of-the-art methods of organic synthesis that describe the use of privileged structures that are of most interest. Chapters included information on benzodiazepines, 1,4-dihydropyridines, biaryls, 4-(hetero)arylpiperidines, spiropiperidines, 2-aminopyrimidines, 2-aminothiazoles, 2-(hetero)arylindoles, tetrahydroisoquinolines, 2,2-dimethylbenzopyrans, hydroxamates, and bicyclic pyridines containing ring-junction nitrogen as privileged scaffolds in medicinal chemistry. Numerous, illustrative case studies document the current use of the privileged structures in the discovery of drugs. This important volume: -Describes the drug compounds that have successfully made it to the marketplace and the chemistry associated with them -Offers the experience from an author who has worked in many therapeutic areas of medicinal chemistry -Details many of the recent developments in organic chemistry that prepare target molecules -Includes a wealth of medicinal chemistry case studies that clearly illustrate the use of privileged structures Designed for use by industrial medicinal chemists and process chemists, academic organic and medicinal chemists, as well as chemistry students and faculty, Privileged Structures in Drug Discovery offers a current guide to organic synthesis methods to access the privileged structures of interest, and contains medicinal chemistry case studies that document their application. |
| 588 0# - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Online resource; title from PDF title page (John Wiley, viewed March 14, 2018). |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Pharmaceutical chemistry. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug development |
| General subdivision | Methodology. |
| 650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Discovery |
| General subdivision | methods. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Chemistry, Pharmaceutical |
| General subdivision | methods. |
| 650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Molecular structure. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 773 0# - HOST ITEM ENTRY | |
| Title | Wiley e-books |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Yet, Larry, author. |
| Title | Privileged structures in drug discovery |
| Edition | Edition 1. |
| Place, publisher, and date of publication | Hoboken, NJ : Wiley, 2018 |
| International Standard Book Number | 9781118145661 |
| Record control number | (DLC) 2017047741 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://eresourcesptsl.ukm.remotexs.co/user/login?url=https://doi.org/10.1002/9781118686263">https://eresourcesptsl.ukm.remotexs.co/user/login?url=https://doi.org/10.1002/9781118686263</a> |
| Public note | Wiley Online Library |
| 907 ## - LOCAL DATA ELEMENT G, LDG (RLIN) | |
| a | .b16755108 |
| b | 2022-10-13 |
| c | 2019-11-12 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Suppress in OPAC | No |
| 914 ## - VTLS Number | |
| VTLS Number | vtls003651167 |
| 998 ## - LOCAL CONTROL INFORMATION (RLIN) | |
| Library | |
| Operator's initials, OID (RLIN) | 2019-05-09 |
| Cataloger's initials, CIN (RLIN) | m |
| Material Type (Sierra) | E-Book |
| Language | English |
| Country | |
| -- | 0 |
| -- | .b16755108 |
No items available.